Reno School of Medicine, University of Nevada, Reno, NV, USA.
Sierra Eye Associates, Reno, NV, USA.
Expert Opin Drug Saf. 2024 Sep;23(9):1109-1114. doi: 10.1080/14740338.2024.2387318. Epub 2024 Aug 5.
Age-related macular degeneration (AMD) is a progressive retinal degenerative disease that is implicated as one of the leading causes of visual impairment in the elderly population. Vascular endothelial growth factor (VEGF) has been identified as the main driver of AMD, and various therapeutics have revolutionized the treatment and management of neovascular AMD (nAMD) with favorable visual and anatomical outcomes.
Physicians have a variety of approved therapeutics in their arsenal for patients with varying disease progression and patient-specific needs, with the ultimate goal of achieving optimal visual and anatomic outcomes. The literature search was conducted using PubMed, Google Scholar, and sources from companies' websites, allowing us to locate findings recently presented at conferences.
Scientific advancements in the field have led to newly approved therapeutics and devices, such as the port-delivery system with ranibizumab (PDS), and further investigation is ongoing in the realm of gene therapy for retinal diseases. In addition to efficacy and durability, newer agents must have comparable safety profiles to older agents in order to be used broadly. These options introduce a level of complexity in nAMD treatment; however, physicians to personalize treatment to improve vision in nAMD patients and reduce treatment burden overall.
年龄相关性黄斑变性（AMD）是一种进行性视网膜退行性疾病，是导致老年人群视力损害的主要原因之一。血管内皮生长因子（VEGF）已被确定为 AMD 的主要驱动因素，各种治疗方法的出现彻底改变了新生血管性 AMD（nAMD）的治疗和管理方式，带来了良好的视觉和解剖学效果。
医生拥有各种经批准的治疗药物可供选择，适用于不同疾病进展和患者特定需求的患者，最终目标是实现最佳的视觉和解剖学效果。文献检索使用了 PubMed、Google Scholar 和公司网站上的资源，使我们能够找到最近在会议上展示的发现。
该领域的科学进步带来了新批准的治疗药物和设备，例如雷珠单抗的输送系统（PDS），并且视网膜疾病的基因治疗领域正在进行进一步的研究。除了疗效和持久性外，新型药物必须具有与旧药物相当的安全性，才能广泛使用。这些选择在 nAMD 治疗中引入了一定程度的复杂性；然而，医生可以根据患者的情况进行个性化治疗，以提高 nAMD 患者的视力并减轻整体治疗负担。
